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Methods: 78 chronic hepatitis B patients who were
given telbivudine 600mg daily were divided in different
groups according to the sex, age, HBeAg seroconversion,
biochemical response and virological response. The rate and
average of CK elevation were analyzed in these groups.
Results: CK elevation was observed in 61.54% patients
(48/78), 69.12% in male (47/68), 10% in female (1/10),
46.15% in seroconversion group (6/13), 60.98% in SVR group
(25/41). High CK elevation (3 times higher then average)
was observed in 4 patients with kinetic intensity during the
treatment.
Conclusion: Sex and seroconversion are the factors related
to CK elevation during telbivudine treatment and the kinetic
intensity is related to high CK elevation level.
PP-099 Evaluating the immunogenicity of TGF-b1
antigen peptide coupled-KLH as anti-hepatic
ﬁbrosis vaccine
S.S. Dang1 *, Y.P. Li1, X.F. Wang1, W.J. Wang1, M. Li1,
Y. Wang1. 1The Department of Infectious Diseases, Second
Afﬁliated Hospital of Medical School of Xi’an Jiaotong
University, Xi’an, 710004, China
Objective: To lay a foundation for the further development
of a novel vaccine based on TGF-b1, a pivotal cytokine,
leading to hepatic ﬁbrosis, we detected the neutralization
activity and evaluated anti-liver ﬁbrosis activity by keyhole
limpet hemocyanin (KLH) coupled TGF-b1 domain antigen
peptide vaccine.
Methods: Possible TGF-b1 domain B-cell epitope was
predicted by bioinformatics, then KLH-coupled peptide was
synthesized by the FMOC method. Hepatic injury model rats
were induced by CCl4 for 10 weeks. 40 male SD rats were
randomly divided into four groups: normal group (olive oil),
adjuvant group (freund’s adjuvant), vaccine group (50 mg
TGF-b1 peptide vaccine+CCl4), model group (CCl4). Serum
TGF-b1 antibody, HA, IV-C, ALT, AST, TBIL, ALB and GLB were
detected; Levels of Hydroxyproline in hepatic tissue were
measured and liver tissues were obtained for pathological
observation.
Results: A certain amount of serum antibody was induced by
TGF-b1 peptide vaccine in vaccine group, but no signiﬁcantly
different statistics were observed compared to other groups
(P> 0.05). The data showed high levels of ALT, TBIL, HA, IV-C
and Hyp in both of model and vaccine groups compared
with normal group respectively (P< 0.05). The ALT, AST and
TBIL levels in vaccine group were lower than model group
(P< 0.05), but HA, IV-C and Hyp content were no statistical
signiﬁcances (P> 0.05). HE and VG staining showed different
degree hepatic ﬁbrosis in model and vaccine groups.
Conclusions: TGF-b1 peptide vaccine cannot remarkably
stimulate antibody production, but the liver function of
vaccine group can be mitigated to some extent.
PP-100 Simulation of clinical data under the therapy of
adefovir by mathematical model
L. Meng1, Y.M. Su1 *, L.Q. Min1. 1University of Science and
Technology Beijing, China
Background: Based on the existing model of virus infection,
we bring up a new model which has logistic growth term and
loss of free virus term caused by virus’s entering uninfected
cells. In this presentation, we do an individual simulation
with the new model to test the consistency of clinical and
simulation data.
Methods: The patient has received a 96 weeks therapy of
Adefovir. The model was described with three variables:
x, y, v and 7 parameters: l, d, b, a, u, p, M, k where p, M
represent uninfected cells’ growth rate and environmental
carrying capacity respectively and the other symbols have
the same meaning as those in the basic Nowak model. We
chose {lambda, d, b, a, u, p, M, k} = {1.2067e+6, 0.0181,
0.1158, 0.0217, 0.1600, 0.0163, 6.6667e+012, 0.0140}.
Results: The clinical data and simulation result are
presented in Table 1.
Conclusion: The simulation data is relatively consistent
with clinical data which means our model can capture the
dynamic character of HBV virus to some extent.
Acknowledgment: This paper is jointly supported by the
Fundamental Research Funds for the Central Universities
(No 06108040) and the Key Special Project of China
(No.2008ZX10502), the National 11 5 Scientiﬁc Technology
Research Program of China.
Table 1: HBV DNA (log copies/ml)
Virus load/weeks 0 12 24 36 48 60 72 84 96
Clinical data 1.27e8 7.78e4 2.28e4 2.28e4 1.84e4 1.22e4 7.73e2 250 250
Simulation data 1.27e8 6.74e5 1.83e5 4.97e4 1.35e4 3.68e3 1.00e3 273.03 74.32
PP-101 A dynamic model of entecavir therapy and after
therapy for HBV Infection
X.J. Zhuo1 *. 1School of Science, Beijing University of Posts
and Telecommunications, China
Background: Entecavir (ETV) is believed to reduce
covalently closed circular DNA. Leonieke et. al gave some
patients’ clinical data of 28 days’ therapy of ETV and the
data after withdraw of therapy. Leonieke et. al also simu-
lated the data by bi-phasic model, but the bi-phasic model
was only simpliﬁcation of Nowak’s basic model under some
conditions. Based on Leonieke et. al’s data and Nowak’s
model, we formulate a new dynamic model to simulate one
patient’s data during and after the ETV therapy.
Methods: A model of HBV is described by four variables: x,
y, v, e, representing uninfected cells, infected cells, free
virus, and immune cells. The model includes 10 parameters:
l, d, b, a, p, k, u, k2, k3, k4 where the meanings of l, d, b,
a, p, k, u are the same as those given in Nowak’s model, k2
represents the curative effect, k3, k4 are relevant to the
immune.
We chose the following parameters during treatment: {l, d,
b, a, p, u, k, k2, k3, k4, k5} = {4.621e5, 6.9e-3, 2.19e-11,
7.3e-3, 1.5e-4, 0.45, 2.37, 2.18, 3e-8, 3.65e-10, 0.1154}.
When the therapy was stopped, we chose {a, u, k2} =
{6.9e-3, 0.25, 0} in which k2 = 0 implies no therapy effect,
a, u becoming smaller means the die rate of infected cells
and free virus decrease after treatment.
Results: Our dynamic model can simulate the patient’s
clinical data during the course of treatment and the rebound
of HBV DNA after withdraw of therapy well.
Conclusion: The difference between the therapy and
withdraw of therapy can be embodied by our model, which
shows our model may possibly capture the dynamics of
anti-HBV infection treatment with ETV.
PP-102 A time-delay HBV therapy mathematical model
for entecavir and adefovir
Y.M. Su1 *, L.Q. Min1. 1School of Mathematics and Physics,
University of Science and Technology Beijing, China
Background: Entecavir (ETV) and Adefovir dipivoxil (AD)
are often used for HBV infection therapy. The use of
Mathematical models to interpret the experimental and
clinical data has made a signiﬁcant contribution to anti-HBV
infections. Based on Jurrien et al’s experimental data with
AD and ETV, considering the time delay of therapy effect
and antiviral drug resistance, we set up a mathematical
model with time delay to simulate the viral dynamics under
the therapy of ETV and AD.
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Methods: A model of HBV is described by: x, y, v, z
which represent uninfected cells, infected cells, free virus,
and CTL cells respectively. Here the infected cells were
divided into two parts with one part having drug resistance
and the other part having none. The model includes
11 parameters: l, d, b, a, p, k1, k2, u, c, b, t. During
treatment of AD, we chose {l, d, b, a, p, k1, k2, u, c, b,
t} = {4.621e5, 6.9e-3, 7.08e-11, 6.9e-3, 1.5e-9, 1, 0.93,
0.08, 0.35, 2.251e-2, 10.6}. During treatment of ETV, we
choose {k2, u, t} = {0.99, 0.18, 1.6{ with other parameters
unchanged. Here the change of the three parameters can
imply the difference of therapy effect of AD and ETV.
Results: The simulation data of our model are qualitatively
agreement with the clinical ones, especially the HBV DNA
decrease when switch to ETV treatment.
Conclusion: The results show that our time-delay therapy
model may possibly capture the dynamics of HBV infection
and anti-HBV infection treatment under different drug.
Acknowledgment: This paper is jointly supported by the
Fundamental Research Funds for the Central Universities
(No. 06108040) and the Key Special Project of China
(No. 2008ZX10502), the National 11 5 Scientiﬁc Technology
Research Program of China.
PP-103 Immune responses elicited in hepatitis B virus
transgenic mice by B7-H1 and HBsAg vaccine
W.J. Su1 *, X.F. Bai1, B. Liu1. 1Tangdu Hospital, The Fourth
Military Medical University, China
Background: The prevalence and infection hepatitis B virus
is a serious problem in the world. Recent studies showed
that the PD-1/PD-L pathway contributed directly to T cell
dysfunction and lack of viral control in established chronic
infection. In the present study, we try to improve the
immune effect of HBsAg vaccination in HBV transgenic mice
by blocking PD-1/PD-L pathway in vivo and to seek new
methods for the treatment of chronic hepatitis B.
Methods: Fifteen HBV Tg mice were randomized into
three groups with 5 mice each, and designated as HBsAg
vaccine group, vaccine and B7-H1 group and control
group, respectively. The anti-HBs of the three groups were
detected by ELISA. The splenocytes of the mice were
stimulated with HBsAg (10mg/ml). The concentrations of
IL-2 and IFN-g were detected by ELISA. The number of IFN-g
secreting cells was measured by ELISPOT.
Results: The anti-B7-H1 in serum was detected in the mice
immunized with B7-H1 and the antibody titer increased
with the immune times. There was no difference of anti-
HBs positive rate between HBsAg group and HBsAg+B7-
H1 group at 6th week and 8th week after immunization.
Concentrations of IL-2 and IFN-g were elevated in both
HBsAg group and HBsAg+B7-H1 group than that in control
group (P < 0.05). Moreover, The numbers of HBs-specifc IFN-g
secreting T cells is also increased in both the HBsAg group
and HBsAg+B7-H1 group when compared with the control
group, and the outcomes showed no difference between
the two experimental groups (P > 0.05).
Conclusion: (1) HBsAg vaccine can increase the cellular and
humoral immune response in HBV Tg mice and reconstruct
immune response to HBsAg. (2) B7-H1 vaccine can not
enhance the humoral and cell immune responses in HBV
Tg mice immunized with HBsAg.
PP-104 Analysis of prognostic factors in patients with
HBV-related liver failure and construction of a
prognostic model to predict patient survival
H.-B. Gao1 *, C. Pan1, M.-H. Lin1, J.-K. Fang1, J.-J. Zhang1,
R. Zhou1, W. Zhou1, L.-J. Xu1. 1The Afﬁliated Infectious
Disease Hospital, Fujian Medical University (Fuzhou
Infectious Diseases Hospital), China
Objective: The aim of this study was to analyze variables
that may affect survival of patients with HBV-related
liver failure, identify the independent predictors for
development of a prognostic survival model, and evaluate
its predictive power.
Methods: In this retrospective cohort study, 569 patients
were diagnosed with HBV-related liver failure between
January 2004 and December 2007. Univariate and
multivariate Cox proportional hazards regression analyses
were applied to such variables as age, sex, disease
complications, biochemical markers, coagulation markers,
and HBV DNA loads to identify independent risk factors
for establishment of a prognostic survival model, and 79
conﬁrmed cases of HBV-related liver failure were used to
evaluate the model’s predictive capacity.
Results: Hepatic encephalopathy, pulmonary infection,
upper gastrointestinal bleeding (UGIB), albumin, AST, creati-
nine, international normalized ratio (INR) were determined
to be independent risk factors (P< 0.01); accordingly, the
prognostic index (PI) = 4.98× hepatic encephalopathy +
4.57×pulmonary infection + 4.41× upper gastrointestinal
bleeding 9.69× Ln(Alb[g/L]) + 2.46× Ln(AST[U/L]) +
5.18× Ln(Cr[mmol/L]) + 3.35×Ln(INR) 15.36, which was
able to accurately predict the 90-d survival.
Conclusions: Survival of patients with HBV-related
liver failure can be accurately predicted based on
seven independent predictors: hepatic encephalopathy,
pulmonary infection, upper gastrointestinal bleeding
(UGIB), albumin, AST, creatinine, and INR. Thus, these
factors might be of reference value in the choice of clinical
treatment.
PP-105 miR-338 3p is down-regulated by the wild
and mutant HBx and inhibits proliferation by
targeting CyclinD1
X.Y. Fu1,2 *, D.M. Tan, Z.H. Hou, Z.L. Hu3,4, G.Z. Liu,
Y. Ouyang, F. Liu. 1Department of Infectious Disease,
2Xiangya Hospital, Central South University, 3The Second
hospital of Nanjing, 4Nanjing, Jiangsu, China
Background: Hepatocellular carcinoma (HCC) is one of
the most common malignancies. Numerous studies have
suggested the potentially oncogenic roles of wild or mutant
hepatitis B virus X protein (HBx) in hepatocarcinogenesis.
To date, however, it remains unknown if HBx regulates
the expression of microRNAs (miRNAs) which negatively
regulate gene expression, playing essential roles in cell
differentiation and carcinogenesis.
Methods: MiRNA microarrays were employed to compare
the expression of cellular miRNAs in the LO2 cell line
that have been successfully established transfecting with
recombinant plasmid pcDNA3.0/HBx-d382, pcDNA/HBx and
plasmid pcDNA3.0 previously. Real-time Quantitative PCR
was used to conﬁrm the chip results. MiR-338 3p was
functionally characterized in LO2 cells with transiently
altered miR-338 3p expression. The direct target of miR-
338 3p was validated using 3′UTR-reporter assay.
Results: Compared with the LO2/pcDNA3.0 cell, a total
of 1 miRNAs exhibited higher expression and 5 miRNAs
demonstrated lower expression in the LO2/HBx-d382 cell,
while 4 up-regulated and 11 down-regulated miRNAs were
observed in LO2/HBx cell. MiR-338 3p, which both down-
